Morgan Stanley Has Lowered Expectations for Humana (NYSE:HUM) Stock Price

Humana (NYSE:HUM) had its price objective cut by Morgan Stanley from $301.00 to $285.00 in a research report report published on Wednesday,Benzinga reports. They currently have an equal weight rating on the insurance provider’s stock.

Several other equities analysts have also weighed in on HUM. Piper Sandler upped their price objective on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a report on Wednesday, January 15th. Wells Fargo & Company dropped their price objective on shares of Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Barclays upped their target price on shares of Humana from $253.00 to $255.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 22nd. Bank of America upgraded shares of Humana from an “underperform” rating to a “neutral” rating and upped their target price for the stock from $247.00 to $308.00 in a report on Wednesday, November 6th. Finally, Truist Financial upped their target price on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a report on Monday, January 6th. Nineteen research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Humana presently has a consensus rating of “Hold” and an average price target of $292.26.

Humana Price Performance

Shares of NYSE HUM opened at $259.93 on Wednesday. The firm’s 50-day moving average price is $273.00 and its 200-day moving average price is $295.72. Humana has a 1-year low of $213.31 and a 1-year high of $406.46. The firm has a market capitalization of $31.30 billion, a P/E ratio of 23.02, a P/E/G ratio of 2.11 and a beta of 0.56. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67.

Humana (NYSE:HUM) last announced its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.18% and a return on equity of 13.20%. Equities research analysts anticipate that Humana will post 16.11 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the sale, the insider now directly owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. This represents a 31.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.32% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Pinnacle Wealth Management Advisory Group LLC grew its position in shares of Humana by 3.6% during the 4th quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,070 shares of the insurance provider’s stock valued at $272,000 after acquiring an additional 37 shares during the period. Atlas Brown Inc. grew its position in shares of Humana by 0.6% during the 4th quarter. Atlas Brown Inc. now owns 6,352 shares of the insurance provider’s stock valued at $1,611,000 after acquiring an additional 38 shares during the period. Moors & Cabot Inc. grew its position in shares of Humana by 2.5% during the 3rd quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider’s stock valued at $519,000 after acquiring an additional 40 shares during the period. Mather Group LLC. grew its position in shares of Humana by 21.0% during the 4th quarter. Mather Group LLC. now owns 236 shares of the insurance provider’s stock valued at $60,000 after acquiring an additional 41 shares during the period. Finally, Capital Advisors Ltd. LLC grew its position in shares of Humana by 26.1% during the 4th quarter. Capital Advisors Ltd. LLC now owns 208 shares of the insurance provider’s stock valued at $53,000 after acquiring an additional 43 shares during the period. 92.38% of the stock is owned by institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.